{"brief_title": "Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure", "brief_summary": "This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.", "condition": "HIV Infection", "intervention_type": "Drug", "intervention_name": "tenofovir", "other_name": "abacavir/lamivudine/zidovudine", "criteria": "Inclusion Criteria: - Currently on an initial HAART (highly active antiretroviral therapy) regimen of 3TC/ZDV or 3TC/d4T and a PI (protease inhibitor) -boosted or unboosted- or NNRTI (non-nucleoside reverse transcriptase inhibitor). - Plasma HIV - 1 RNA was <400 copies/ml on at least 2 documented occasions prior to viral rebound. - Have a plasma HIV - 1 RNA value >400 copies/ml and <10,000 copies/ml on 2 documented successive occasions (including screen) separated by at least 2 weeks. - A CD4+ lymphocyte count less than or equal to 100. Exclusion Criteria: - Have not taken Abacavir (ZIAGEN or TRIZIVIR) or tenofovir (VIREAD) previously. - Have not had an AIDS defining illness within 30 days of screen. - Pregnant or breast-feeding. - Specified viral genotypes upon screening. - And other inclusion or exclusion criteria to be evaluated by the physician.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00038506.xml"}